Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rang in Aktien #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aktienkurs
$0.11725176
Zuletzt synchronisiert: 2025-07-14
Marktkapitalisierung
$481.50K
Veränderung (1 Tag)
-0.20%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategorie

Dividendenrendite-Verlauf für PHAXIAM Therapeutics S.A. (PHXM)
Dividendenrendite (TTM) von PHAXIAM Therapeutics S.A. (Aktienkürzel: PHXM) zum 2022-12-31: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für PHAXIAM Therapeutics S.A. (PHXM) von 2016 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber